Antibodies

8 May 2013

Real-world data at ARVO highlight transformational outcomes seen with Lucentis®, including lower injection frequency than in original clinical trials

8 May 2013

Amgen Announces Top-Line Results of Vectibix® (panitumumab) Phase 3 Head-to-Head Study Against Erbitux (cetuximab) in Metastatic Colorectal Cancer

7 May 2013

Opsona Therapeutics Ltd. Initiates a Phase II Study with OPN-305, a First-in Class Monoclonal Antibody that Blocks Toll-Like Receptor 2, in Renal Transplant Patients at High Risk of Delayed Graft Function

7 May 2013

Baxter Announces Topline Results of Phase III Study of Immunoglobulin for Alzheimer’s Disease

7 May 2013

ABLYNX STARTS PRE-CLINICAL DEVELOPMENT OF ALX-0962, AN ANTI-IgE NANOBODY, TO TREAT SEVERE ALLERGIC ASTHMA

5 May 2013

Emergent BioSolutions Presents Preclinical Efficacy Data on ES414 Its Lead ADAPTIR Bispecific Therapeutic for Prostate Cancer

5 May 2013

Regeneron Acquires Full Rights to Two Novel Ophthalmology Development Programs

5 May 2013

Ambrx Initiates Collaboration with Bristol-Myers Squibb for Discovery, Development of Next-Generation Antibody Drug Conjugates

2 May 2013

Daratumumab Receives Breakthrough Therapy Designation in Double Refractory Multiple Myeloma from U.S. Food and Drug Administration

2 May 2013

Acceleron and Shire Conclude Collaboration on ACE-031

1 May 2013

Genmab Announces Top-Line Phase II Results for Ofatumumab Combined With Bendamustine in Untreated and Relapsed Chronic Lymphocytic Leukemia

1 May 2013

Intas launches Mabtas

1 May 2013

Cipla launches the first Biosimilar of Etanercept in India under the brand name ‘ETACEPT’ for the treatment of Rheumatic Disorders

30 April 2013

FDA Approves ACTEMRA® for Children Living with a Rare Form of Arthritis

29 April 2013

Opsona Therapeutics Limited raises €33 million (USD 43 million) oversubscribed Series C equity financing to advance clinical development of its lead product OPN-305

29 April 2013

Peregrine Announces Completion of Patient Enrollment in Breast Cancer Clinical Trial for Bavituximab

29 April 2013

Merrimack Pharmaceuticals Completes Enrollment of Second Cohort in Phase 2 Study of MM-121 in Non-Small Cell Lung Cancer

28 April 2013

MorphoSys Initiates Phase 2 Study of Anti-CD19 Antibody MOR208 in B-cell Acute Lymphoblastic Leukemia

26 April 2013

Celltrion initiates phase 1 clinical trial of therapeutic antibody against universal influenza.

25 April 2013

XBiotech Enrolls First Patient in Phase III Pivotal Trial of Xilonix

25 April 2013

Daiichi Sankyo Enrolls First Patient in Nimotuzumab Phase 3 Clinical Trials

24 April 2013

arGEN-X advances ARGX-113 into preclinical development for autoimmune disorders

24 April 2013

Merck Announces Breakthrough Therapy Designation for Lambrolizumab an Investigational Antibody Therapy for Advanced Melanoma

23 April 2013

Mayo Clinic and Acorda Therapeutics Announce Initiation of Phase 1 Trial of Remyelinating Antibody in People with Multiple Sclerosis

22 April 2013

Kymab Announces Kymouse Antibody Discovery Agreement With Novo Nordisk

22 April 2013

BioInvent Initiates Clinical Trial with BI-505 in Smoldering Myeloma

18 April 2013

TRACON Pharmaceuticals Announces Publication of Mechanism of Action of TRC105, a Novel Anti-Angiogenic Antibody

17 April 2013

Compugen Discloses Focused Target Discovery Program for Antibody-Drug Conjugate Cancer Therapy

17 April 2013

Lilly Announces Positive Results of Phase III Trials of Dulaglutide in Type 2 Diabetes

15 April 2013

Merrimack Pharmaceuticals Completes Enrollment of One Cohort in Neoadjuvant Phase 2 Study of MM-121 in HER2-Negative Breast Cancer

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

2FOR1 Report Package: Vectorized Antibody and Prodrug Antibody & Cytokine landscape analysis report package with 50% discount

Targeted Protein Degradation by Novel PROTACs and Molecular Glues 2020: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective

2020 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

Antibody Target, Technology & Pipeline Database: 1-Year Subscription

Ustekinumab (Stelara) Biosimilars Pipeline Review

2022 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

Omalizumab (Xolair) Biosimilars & Biosuperiors Pipeline Review

TROP-2-Targeted Immunotherapy Pipeline Review

GPRC5D-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

2021 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics